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Abstract
Patients with epidermal growth factor receptor (EGFR) mutation positive non-small cell lung
cancer (NSCLC) have several EGFR targeting tyrosine kinase inhibitors (TKIs) available in frontline management. However, the disease will inevitably progress over time due to acquired
resistance. Longitudinal tumor profiling for genomics guided therapy is indicated upon disease
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progression. It is a common scenario yet, when after failure of EGFR-TKIs, potentially actionable
genomic alterations are lacking. Management of such patient is challenging with very limited
options available. Combination of chemotherapy, anti-vascular/anti-angiogenic and immunecheckpoint inhibitors may become a salvage option for such patients. Here we describe a case
of TKI refractory EGFR-mutant NSCLC successfully treated with carboplatin, paclitaxel, atezolizumab and bevacizumab combination with remarkable prompt tumor response.
© 2019 The Author(s)
Published by S. Karger AG, Basel

Introduction

Despite excellent initial overall response to targeted EGFR (see Table 1 for glossary) therapy reaching 70–80%, essentially all patients with EGFR-mutant NSCLC inevitably progress
over time due to acquired drug resistance, thereby limiting their long term survival benefits.
Multiple mechanisms of acquired resistance against first-generation EGFR TKIs (erlotinib and
gefitinib) have been described, with about half of the cases attributed to the exon 20 gatekeeper EGFR-T790M (c.2369C>T) mutation [1–3].
Osimertinib is the only available FDA-approved TKI active against T790M, and recently it
has further been approved as first-line therapy in EGFR mutant lung cancer patients based on
the FLAURA study [4]. In this study, the median duration of response to osimertinib reached
17.6 months (95% CI, 13.8 to 22.0) as compared to 8.5 months (95% CI, 7.3 to 9.8) with first
generation TKIs [4]. For patients who develop disease progression on EGFR TKIs, further
treatment options are limited. This is particularly true for those who progress on osimertinib,
with emerging drug-resistant C797S(c.2390G>C) mutation, which currently is lacking standard therapeutic options [5].
Cytotoxic chemotherapy only yields limited and short-lived responses in general with numerous adverse effects. Attempts to incorporate immune checkpoint inhibitors in patients
with EGFR-driven NSCLC have initially been also disappointing, especially when used as a single agent programmed death-1 (PD-1) or PD-ligand 1 (PD-L1) antibody [6–8]. Recently, promising data has emerged with overcoming immune checkpoint inhibition resistance by combining it with anti-angiogenic agents. It is believed that anti-vascular endothelial growth factor
(VEGF) not only promotes anti-angiogenesis but also acts as a key mediator of the immunosuppressive microenvironment that enables tumor cells to evade immune surveillance [9].
Combining anti-VEGF and immune checkpoint inhibitors has recently been shown to work
synergistically in several tumor types.
Case Report

A 45-years-old Caucasian female, who was a never-smoker and previously healthy, presented with progressive forgetfulness and confusion. MRI of the brain demonstrated multiple
metastatic lesions, with the dominant mass in the left frontal lobe measuring 1.5 cm associating with extensive vasogenic edema. She was diagnosed with metastatic lung adenocarcinoma
of right upper lung with involvement of mediastinal lymph nodes, brain, liver and bones. She
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underwent craniotomy with resection of the largest brain lesion revealing the diagnosis. Histological and immunohistochemical tumor characteristics are illustrated in Fig. 1. Patient then
received stereotactic radiosurgery to the 8 largest brain metastatic lesions followed by whole
brain radiotherapy. As part of a comprehensive molecular tumor profiling (Caris Molecular
Intelligence; Caris Life Sciences, Phoenix, AZ), her tumor was found to be positive for EGFR
exon 19 deletion (E746-A750del) and a TP53 mutation (Table 2). It was negative for ALK or
ROS1 rearrangements, KRAS or BRAF mutations and also negative for PD-L1 expression.
Patient was started on erlotinib 150 mg daily as first-line therapy and had a near-complete response on follow-up restaging imaging. Nine months later, she developed oligo-progressive disease with two new skeletal lesions which were treated with local stereotactic body
radiotherapy and erlotinib was continued at that time. Over the following 8 months, a similar
approach was applied to several other gradually progressive skeletal metastases while further
therapeutic options were explored. One of these drug-resistant metastatic skeletal lesion in
the pelvis was rebiopsied but yielded no informative molecular insights on repeat molecular
profiling. Circulating tumor DNA (ctDNA; also referred to as cell-free DNA, cfDNA) liquid biopsy testing (Guardant360; Guardant Health; Redwood City, CA) was performed and detected
the presence of T790M mutation (5.4% of altered cell-free DNA (Fig. 2, Fig. 3A). Based on this
finding, patient was started on osimertinib 80 mg daily. She again had an excellent response
with a progression-free duration lasting for 12 months. Subsequently she again developed oligoprogressive skeletal metastases, which were successfully managed with local radiotherapy
concurrently with osimertinib over the next 6 months. She ultimately progressed on osimertinib more extensively beyond further radiotherapy control on TKI, including multiple mediastinal nodal progression. Mediastinal lymph node rebiopsy was obtained confirming adenocarcinoma histology without transformation, but material was insufficient for broad-based
molecular testing. Repeat cfDNA liquid biopsy revealed no EGFR mutations (Fig. 3B).
For the third-line of treatment patient was started on a quadruplet combination of carboplatin AUC 6, paclitaxel 200 mg/m2, bevacizumab 15 mg/kg and atezolizumab 1,200 mg
(ABCP), based on encouraging data from the IMpower 150 study [10]. The first treatment cycle was complicated by subclinical thyroiditis, grade 3 nausea, vomiting and pancytopenia requiring hospital admission. The second cycle was delayed with also a dose reduction on the
cytotoxics. Nevertheless, restaging PET/CT scan at week 6 after only one cycle of treatment
already demonstrated a near-complete response (Fig. 4). Patient subsequently completed total of 4 cycles of ABCP followed by maintenance bevacizumab and atezolizumab (AB). She remained in radiographic remission for 9.5 months when her repeat restaging PET/CT scan
demonstrated enlarging FDG-avid primary RUL lung nodule and several new skeletal lesions
and brain MRI revealed new tiny enhancing foci in right frontal and left parietal cerebral cortex. At this time, patient was agreeable for treatment with repeat local radiotherapy to drugresistant disease lesions while continuing immune checkpoint PD-L1 therapy on atezolizumab
maintenance. Bevacizumab was temporarily held during the time of radiotherapy. She has received GKRS to brain lesions and the plan is to continue with focal radiation to skeletal metastases. Repeat cfDNA liquid biopsy profiling at time of ABCP/AB regimen acquired resistant
progression revealed re-emergence of EGFR exon 19 deletion and new emergence of CDK6
amplification and ATM R3008C mutation (Fig. 3C). Besides, there was a new CDK12 mutation
of unknown significance; and the TP53 as well as EGFR T790M mutations remained undetectable. Overall, it was determined that no new readily targetable alterations were found.
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Discussion/Conclusion

Despite the advent of targeted EGFR-TKIs like erlotinib and osimertinib, the development
of drug resistance remains a formidable challenge in the management of EGFR-mutant NSCLC.
Multiple mechanisms of acquired drug resistance have been described in the literature, supporting longitudinal tumor profiling for genomics guided therapy. While T790M mutation represents the dominant mutational resistance mechanism against early generation EGFR-TKIs,
there is emerging data describing an acquired mutation in C797 codon of EGFR leading to osimertinib resistance [5]. This mutation has no therapeutic options presently although there is
potential 4th generation EGFR-TKI in clinical development [11]. Other possible mechanisms
of resistance include activation of alternative bypass pathways (MET, HER2, KRAS, BRAF,
PIK3CA) or oncogenic fusions (CCDC6-RET, FGFR3-TACC3, EML4-ALK), some of which can be
exploited with therapeutic interventions [1, 2, 12].
In a real life practice however, as in our presented case, by the time acquired EGFR-TKI
resistance develops, commercially available effective therapeutic options are limited and clinical trials are not always readily available. The recent exciting achievement of targeting the
immune checkpoint pathway in cancer therapy including NSCLC has not yet significantly impacted patients with most oncogenic-driver mutations, especially in EGFR and ALK. Most, if
not all, of the clinical studies testing immune checkpoint inhibitors excluded patients with
known EGFR mutations and ALK-rearrangements. Studies in second-line immunotherapy trials in EGFR-mutated NSCLC patients yielded disappointing response and failed to demonstrate any survival advantage when compared with docetaxel [6–8]. Moreover, combination
strategy with addition of immunotherapy to targeted TKIs have also proven to be associated
with significant treatment toxicities [13]. Oncogene-driven lung tumors, e.g. EGFR mutation
and ALK-rearrangement, were found to correlate with low tumor mutational burden and often
also low PD-L1 expression [14]. It is conceivable that these factors above could account for
the relative lack of response and treatment efficacy of immune checkpoint inhibitors in this
patient population. Furthermore, even in those with high PD-L1 expression, this was not
highly predictive for positive responses either.
The anti-VEGF antibody bevacizumab combined with chemotherapy was approved for
the treatment of metastatic NSCLC in combination with carboplatin and paclitaxel based on
the ECOG 4599 study in 2006 [16]. The anti-VEGF strategy has been investigated in the IMpower 150 study as a potentiating option in combination with the immune checkpoint PD-L1
inhibitor atezolizumab [10]. The concept behind combining anti-angiogenic agents with immune checkpoint inhibitors is at least partially based on the demonstration that VEGF is not
only important for tumor neovascularization, but is also a key immuno-modulating factor produced by solid tumors to evade immune recognition and tumor cell killing [9, 15]. The IMpower 150 study included a small cohort of EGFR mutation positive NSCLC patients (35/400
or 8.8%) who progressed on prior EGFR-TKI therapy and were assigned to receive ABCP regimen in comparison with patients who received the same regimen without atezolizumab
(BCP). In the subgroup analysis, the median progression-free survival (PFS) in patients with
EGFR mutation or ALK-rearrangement in the ABCP combination arm was 9.7 months which
was significantly longer compared to the BCP arm, 6.1 months respectively with unstratified
hazard ratio 0.59. The difference was favorably comparable to the entire study cohort of
NSCLC patients receiving ABCP combination [10].
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The presented case herein illustrates a classic natural history of EGFR-mutant NSCLC. It
also provides support for the utility of consolidative local radiotherapy against oligo-progressive lesions beyond EGFR TKI acquired drug resistance. After repeated resistance to erlotinib
and osimertinib, our patient ultimately achieved a near-complete response after only one cycle of ABCP regimen, demonstrating the possible prompt and remarkable efficacy of the combination strategy in this heavily-pretreated disease scenario. Our patient continued to do well
on maintenance AB treatment for 9.5 months of progression-free interval with excellent performance status, and overall >4 years since her initial metastatic cancer diagnosis. Notably,
her original tumor stained negative for PD-L1 expression and highlighted rare CD4 and CD8
positive lymphocytes (Fig. 1). However, the 9.5 months duration of response was less than
ideal but was also comparable with the outcome in the original IMpower 150 study. She then
developed disease progression including CNS involvement. Repeat cfDNA liquid biopsy on
ABCP/AB progression demonstrated no readily targetable alterations. Our knowledge on molecular mechanisms in ABCP acquired resistant diseases is very limited at present, but expectedly more studies would continue to emerge in the near future. To our best knowledge, this is
the first molecular profiling report of a case of ABCP regimen acquired drug resistant progression. Interestingly, our liquid biopsy molecular profiling at ABCP/AB acquired resistant progression identified novel molecular aberrations, i.e. CDK6 amplification, ATM R3008C, that
might represent the genomic driving events behind the drug resistance development on combination of cytotoxic chemotherapy with anti-angiogenic and immune checkpoint inhibitors.
While CDK6 amplification is associated with CDK inhibitor resistance thus negating such therapeutic option for our patient, the ATM mutation leading to genomic instability might offer a
novel therapeutic opportunity with a PARP and/or an ATM/ATR inhibitor [17].
In conclusion, the PD-L1 immune checkpoint therapy incorporated ABCP regimen provides a promising salvage therapeutic option for patients with EGFR-mutation driven NSCLC
resistant to targeted TKIs, especially beyond osimertinib. The data from IMpower 150 study
provides further support to the development of combinational strategies using chemotherapy,
anti-vascular/anti-angiogenic and immune checkpoint inhibitors in these patients. However,
clinically validated predictive biomarkers for response to immunotherapy-containing salvage
regimens for these patients are still grossly lacking. It is also unclear at present time how the
ABCP regimen will compare to secondary targeted therapy approaches if they are uncovered
on repeat biopsy and genomic profiling. We propose that randomized clinical studies using
this novel combinational strategy should be conducted with a focus on EGFR-mutant and other
oncogene-addicted NSCLC in order to fully validate this clinical hypothesis and to resolve the
related clinical issues outlined above.
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Fig. 1. Histological and immunohistochemical characteristics of the metastatic tumor. A. Metastatic adeno-

carcinoma to the brain (H&E at 200×); B. An immunohistochemical stain for CD4 at 200× highlights rare
lymphocytes and non-specific staining; C. An immunohistochemical stain for CD8 at 200× highlights rare
lymphocytes; D. A CD34 immunohistochemical stain at 200× highlights endothelium; E. An immunohistochemical stain for PD-L1 (22C3) highlights rare weak tumor cell membranous staining, rare positive staining in lymphocytes.
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Fig. 2. Summary longitudinal liquid cfDNA profiling (Guardant360) with the tumor response map.
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Fig. 3. Longitudinal liquid cfDNA profiling (Guardant360) results. (A) New emergence of acquired EGFR

T790M mutation with 5.4% allele frequency of altered circulating cell-free DNA (% cfDNA) demonstrated
on erlotionib progression, which disappeared in the following 2 serial liquid biopsies while on osimertinib,
during profiling upon drug resistance to osimertinib (B). Subsequent profiling on ABCP progression revealed the presence of initial driver EGFR exon 19 deletion (E746-A750del specific) without EGFR T790M
mutation, and new additional alterations (CDK12 N1208S, ATM R3008C and CDK6 amplification) (C).
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Fig. 4. PET/CT scans prior to initiation of ABCP therapy (A) and after one cycle of treatment (B), shown.

Remarkable and prompt near-complete response with radiographic and metabolic resolution of extensive
mediastinal lymphadenopathy and left pelvis bony metastases in resistant progression against osimertinib
was noted after the 1st cycle of ABCP salvage treatment (arrows).
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Table 1. Glossary of genomic terms and nomenclature

EGFR

Epidermal growth factor receptor, transmembrane receptor tyrosine kinase

T790M
(c.2369C>T)

This pathogenic mutation occurs within exon 20 of EGFR kinase domain and results
in an amino acid substitution at position 790 from a threonine (T) to a methionine
(M)

C797S
(c.2390G>C)

This pathogenic mutation occurs within exon 20 of EGFR kinase domain and results
in an amino acid substitution at position 797 in EGFR, from a cysteine (C) to a serine
(S)

PD-1

Programmed cell death protein 1, is a receptor expressed on T-cells, activation of
which causes suppression of immune response

PD-L1

Programmed death ligand 1, transmembrane protein, regulating immune response
by interacting with PD-1 receptor

Exon 19 deletion
(E746-A750del)

In-frame deletions occurring within exon 19 of the EGFR kinase domain, one of the
most common EGFR mutations in NSCLC

TP53

Tumor protein p53 is a gene that codes for a tumor suppressor protein

ALK

Anaplastic lymphoma kinase, transmembrane receptor tyrosine kinase

ROS1

ROS proto-oncogene 1, integral membrane protein receptor tyrosine kinase

KRAS

KRAS proto-oncogene, GTPase

BRAF

B-Raf proto-oncogene, serine/threonine kinase

TPS

Tumor proportion score

MET

c-Met protooncogene

FISH

Fluorescence In Situ Hybridization

CDK12

Cyclin dependent arginine-serine kinase 12, regulating cell cycle progression and
transcription

ATM

Ataxia-Telangiectasia serine/threonine kinase, involved in double-strand DNA damage repair

CDK6

Cyclin dependent serine/threonine protein kinase 6, regulating cell cycle progression
and transcription

ATR

Ataxia telangiectasia and Rad3-related serine/threonine-protein kinase, involved in
single-strand DNA damage repair
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Table 2. Comprehensive tumor molecular profiling analysis of case tumor specimen by Caris Molecular In-

telligence (CMI)
Genes tested with alterations
Gene

Alteration

Frequency, %

Exon

Result

EGFR
TP53

E746_A750del
C176F

71
42

19
5

Mutated, pathogenic
Mutated, pathogenic

IDH1
IDH2
JAK2
KDR (VEGFR2)
KRAS
MEK1
MEK2
MLH1
MPL
NF1

NOTCH1
NRAS
NTRK1
PDGFRA
PDGFRB
PIK3CA
PTCH1
PTEN
RAF1
RET

Genes tested with no mutations detected
ABL1
AKT1
ALK
Androgen receptor
APC
ARAF
ATM
BAP1
BRAF
BRCA1

BRCA2
c-KIT
CDK4
CDKN2A
CHEK1
CHEK2
c-MET
CSF1R
CTNNB1
DDR2

Her2/neu (ERBB2)
ERBB3
FGFR1
FGFR2
FGFR3
FLT3
GNA11
GNAQ
GNAS
HRAS

ROS1
SMO
SRC
VHL
WT1

